Skip to main content
  • Letter to the Editor
  • Open access
  • Published:

Pathogenic somatic alterations of DDR genes in lung cancer are significantly different from germline mutations and are associated with more unstable genomes

To the Editor

The defects DNA-damage repair (DDR) genes would drive tumor formation and are associated with increased genomic instability and tumor mutational burden (TMB) in cancer [1]. Although, alterations of DDR genes are common in NSCLC, the differences between the germline and somatic alterations are poorly characterized.

The DNA sequencing data of 540 genes from 5235 lung cancer patients were retrospectively collected and 276 DDR genes were analyzed [2]. The variations were annotated as pathogenic (P), likely pathogenic (LP), and non-pathogenic (NP) according to ACMG (American College of Medical Genetics) guideline. The patients were divided into 3 groups (Table 1): DDR-germline (P&LP germline variants, N = 650), DDR-somatic group (only P&LP somatic variants, N = 1489) and the non-DDR group (NP variants, N = 3096). The DDR-somatic group had a higher median age and the highest proportion of males, stage IV and LUSC patients.

Table 1 Comparison of clinical data for NSCLC patients in non-DDR, DDR-somatic, and DDR-germline groups

The most commonly germline alterations were found in BRCA2 (8.46%), ERCC2 (8.15%) and IDH1 (8%), while in the somatic mutations, TP53 (89.05%) showed the highest frequency (Fig. 1A, B). Among the ten functional categories of DDR genes, the mutations of Fanconi anemia (FA) (234, 36.00%) and homology-dependent recombination (HR) (249, 38.31%) signaling were enriched in germline, while other categories (1417, 95.10%) were more common in somatic alterations.

Fig. 1
figure 1

DDR gene mutation landscapes of the DDR-germline (A) and DDR-somatic (B) groups and the comparation of the alterations in actionable genes among the three groups (C)

In pairwise comparisons of the three groups, 28 actionable mutations were assessed based on OncoKB [3]. DDR-somatic group was more likely to have alterations in PTEN (OR = 0.46), FGFR1 (OR = 0.48), NTRK1 (OR = 0.46) compared with DDR-germline group. Taken non-DDR group as reference, mutations in ALK (OR = 1.94), CDK12 (OR = 2.62), STK11 (OR = 1.58) were more common in DDR-germline group, but CDKN2A (OR = 2.13), NF1 (OR = 2), NTRK3 (OR = 2.06) in DDR-somatic group (Fig. 1C).

The tumor mutational burden (TMB) was statistically different among the three groups (P < 2.22e−16). The DDR-somatic group exhibits the highest median TMB (12.39) compared with 7.44 in DDR-germline and 5.24 in non-DDR group. In addition, the proportion of MSI-H patients in DDR-somatic group is the highest (0.94%) compared with 0.62% in DDR-germline group and 0.23% in non-DDR group (P = 0.0040) (Fig. 2A).

Fig. 2
figure 2

The differences of TMB in the DDR-germline, DDR-somatic and non-DDR groups (A) and the immune microenvironment assays in the DDR mutation and wild type groups (B)

The genetic data of 1053 lung cancer patients were downloaded from TCGA. The TCGA cohort was stratified into DDR-somatic and non-DDR groups according to the pathogenic annotation by Clinvar. Ten types of immune cells were found significantly associated with DDR status (Fig. 2B), Macrophages M0 (P = 0.0126), Macrophages M1 (P = 0.0002) and CD8 T cells (P = 0.0087) showed higher proportions in DDR-somatic group.

The differences in the mutation profile between the DDR-germline and DDR-somatic groups and the distinct actionable genes may indicate the different target-therapy choices for NSCLC patients. Besides, patients with somatic pathologic mutations exhibit the highest genome instability, including the highest TMB and the most MSI-H, and superior immune microenvironment consist of higher proportions of macrophages and CD8 cells infiltration. According to a previous report, patients with pathologic DDR mutations had higher objective response rate, longer median progression-free survival and overall survival with PD-L1 therapy [1]. This may indicate patients with somatic DDR alterations may better benefit from the immune checkpoint inhibition in NSCLC.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.


  1. Ricciuti B, Recondo G, Spurr LF, et al. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020;26(15):4135–42.

    Article  CAS  PubMed  Google Scholar 

  2. Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23(1):239-254 e236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


We thank Mr. Ran Ding, Mr. Guanghua Lu, and Mr. Wanglong Deng from Simcere Diagnostics for the kindly assistance.


This work was funded by the National Natural Science Foundation of China (No. 82070206) and Tianjin Key Medical Discipline(Specialty) Construction Project (No.TJYXZDXK-053B).

Author information

Authors and Affiliations



HW: Conceptualization, Writing—Original Draft. YZ: Visualization, Investigation. XZ, NL: Data analysis, Writing—Original Draft. FW, TS: Writing—Original Draft. CQ: Methodology, XL: Conceptualization, Writing- Reviewing and Editing. All author read and approved the final manuscript.

Corresponding author

Correspondence to Xin Li.

Ethics declarations

Ethics approval and consent to participate

This study used desensitized patient data for analysis and the ethics approval was waived.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, H., Zhao, Y., Wang, F. et al. Pathogenic somatic alterations of DDR genes in lung cancer are significantly different from germline mutations and are associated with more unstable genomes. J Transl Med 20, 408 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: